The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis
J. Clin. Invest. Daniela Cota, et al. 112:423 doi:10.1172/JCI17725 [Go to this article.]

Figure 5
Functional CB1 is expressed in adipocytes. (a) RT-PCR for CB1 performed on CB1+/+ and CB1–/– epididymal fat pads. Ma, marker; lane 1, CB1+/+; lane 2, CB1–/–; lane 3, negative control for CB1+/+; lane 4, negative control for CB1–/–; lane 5, hippocampus; lane 6, water. (b) RT-PCR for CB1 performed on primary adipocyte cell cultures from C57BL/6N mice. Ma, marker; lane 1, C57BL/6N adipocytes; lane 2, negative control; lane 3, hippocampus; lane 4, water. (c) Effects of different doses of the CB1 agonist WIN-55,212 (WIN) and CB1 antagonist SR 141716A (SR) on heparin-releasable LPL activity (expressed as percentage of vehicle control) in primary adipocyte cells from C57BL/6N mice. *P < 0.05 compared with vehicle control. ^†P < 0.05 compared with 10^–6 M WIN.